Month: October 2018

New classes of drugs fully funded from 1st Oct 2018: vildagliptin and sacubitril/valsartan

Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor approved for the treatment of type 2 diabetes. See BPAC article for further information.
Sacubitril/valsartan is approved for the treatment of symptomatic chronic heart failure with LVEF ≤40%. Sacubitril is a neprilysin inhibitor (inhibits breakdown of natriuretic peptides increasing diuresis, natriuresis, and vasodilation) and valsartan is an angiotensin-2 receptor blocker. See NZF and American College of Cardiology’s expert analysis for further information.

Upcoming bulletins:

  • CAM: St John’s wort
  • Repackaging of dabigatran into compliance packs